▶주메뉴 바로가기
▶본문 바로가기
The management conflict within the founding family of Hanmi Pharmaceutical Group ended, as the sons of founder Lim Sung-ki -- Lim Jong-yoon and Lim Jong-hoon -- secured a majority within Hanmi Science’s board at the general meeting of shareholders last week. However, there are still multiple hurdl...
The global rise in popularity of K-beauty brands has brought attention to Kolmar Korea, a leading cosmetics original design manufacturer that has secured a whopping 70 percent market share in the sun care sector alone here. According to the company Sunday, its “Fitting SPF Boosting” technology h...
The expected merger between OCI Group and Hanmi Group has been called off after a general meeting of shareholders at Hanmi Science, the holding company of Korea's leading drug firm Hanmi Pharmaceutical, on Thursday. The management conflict within the founding family has also temporarily ended as L...
South Korea’s growing biopharmaceutical production capacity is increasingly making the country an attractive investment destination for global life science companies, industry sources said Thursday. Since 2016, global pharmaceutical and biotech firms started building their research and developmen...
The trade ministry said Thursday it has discussed a possible investment opportunity in South Korea with a major US biotechnology firm, as the country aims to become a global manufacturing hub in the industry. Trade Minister Cheong In-kyo met Mark Smedley, a senior vice president of Thermo Fisher S...
SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, on Monday unveiled its latest strategic initiative, aimed at preparing for possible pandemics in the future and expanding into emerging sectors in the post-COVID-19 era. The new strategy, dubbed SKBS 3.0 Reboot, focuses on bro...
German pharmaceutical group Merck Life Science said Thursday the company will invest around 300 million euros ($326 million) to build a new bioprocessing complex in South Korea, its largest investment yet in the Asia-Pacific region. The new investment comes as the company renews its commitment to ...
South Korean pharmaceuticals firm SK Bioscience said Thursday that it exported its cell-cultured flu vaccine, SKYCellflu, to Thailand, marking its first entry into a market with southern hemisphere requirements. The company shipped out approximately 440,000 doses of SKYCellflu to its Thai partner ...
SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, said Thursday the company has exported its influenza vaccine to Thailand as part of efforts to expand its business presence in the southeast Asian market. The company has shipped around 440,000 doses of SKYCellflu, a cell-cult...
Global pharmaceutical company Merck Life Science said Thursday it will invest some 430 billion won ($324 million) to build a new bioprocessing production facility in South Korea. The European bio firm plans to build a 43,000 square-meter center in Daejeon, about 140 kilometers south of Seoul, equi...
The ongoing tug-of-war between the South Korean government and medical professionals over the proposed increase in the number of medical students could have negative impacts on local drug companies’ revenues as well, industry sources said Tuesday. According to officials from local pharmaceutical ...
Korean biopharmaceuticals firm Celltrion announced Monday that its new autoimmune disease treatment Zymfentra has been launched in the US market. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab Remsima. In October last year, the US Food and Drug Administration approved ...
South Korean biopharmaceutical firm Celltrion said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the US market. Zymfentra, a subcutaneous injection formulation of Celltrion's infliximab Remsima, won approval from the US Food and Drug Administration last year for use o...
South Korean pharmaceutical giant Yuhan has decided to reinstate the chairperson and vice chairperson positions for the first time in 28 years, since Chairman Yeon Man-hee stepped down from his post in 1996. Yuhan shareholders approved changes to the articles of incorporation to reestablish the po...
Samsung Biologics is off to a promising start this year with two large-scale contract manufacturing deal signings in March alone. According to Samsung Biologics on Wednesday, the company recently inked a contract manufacturing deal with MSD Switzerland, worth some $71 million. The deal, set to exp...
Korean investors dump Kospi, flock to US stocks despite strong dollar
Hanwha sets up financial AI center in San Francisco
Korea, Indonesia strengthen partnership in general insurance
Cheaper Chinese chips hamper profit outlook for Samsung, SK hynix
Chinese battery makers gobble up Korean shares
Global talent market expands as professionals eyes abroad